CV CapsoVision, Inc

CV financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1378325 Exchange: Nasdaq SIC: 3845 (Electromedical & Electrotherapeutic Apparatus) Latest filing: 10-Q filed Aug 13, 2026 Data checked: Oct 21, 2026
Showing 2 of 2 annual and 0 of 8 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$0 (Jun 2025)
Industry (SIC)
3845 Electromedical & Electrotherapeutic Apparatus
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(408) 370-4790
EIN
203369494
Headquarters
SARATOGA, CA, 95070
Former Names: Capso Vision Inc (2006–2014)

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
$13.89M
Net Income
$-29.83M
Total Assets
$18.57M
Total Equity
$13.17M
Total Debt
-
Free Cash Flow
$-27.89M
Ratios
Gross Margin
50.9%
Operating Margin
-217.1%
Net Margin
-214.7%
Return on Equity
-226.6%
Return on Assets
-160.6%
Current Ratio
3.35x
FCF / Assets
-150.2%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

CapsoVision, Inc generated $13.55M of revenue in fiscal 2025, with net loss of $25.32M and an operating cash outflow of $22.86M. The $13.55M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Compared with $11.76M in fiscal 2024, revenue recorded a 15.3% year-over-year increase. On a per-share basis, diluted EPS was -$1.03, which connects the reported earnings outcome with the company’s diluted share count. The diluted weighted-average share count was 24.56M, linking total earnings with the per-share result received by shareholders. The company employed $18.16M of total assets, the balance-sheet base supporting its current operating and cash-flow results. Asset turnover was 0.75x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

After reported cost of revenue, the company retained $7.17M as gross profit before recognizing operating expenses and other items. Gross profit represented 52.9% of revenue, showing how much of the top line remained after direct costs. The company recorded an operating loss of $25.52M after the reported operating expense base. Relative to revenue, the operating deficit measured 188.3%, showing the shortfall after operating costs. The company ended the period with a net loss of $25.32M, extending the operating result through all remaining items. The net loss equaled 186.8% of revenue, showing the bottom-line deficit relative to the company’s sales base. Negative EBITDA totaled $25.30M, confirming that the earnings deficit remained before depreciation and amortization. The pretax result was a loss of $25.29M, establishing the deficit before tax effects. Measured against revenue, the pretax deficit represented 186.6%. The company recognized $24.00K of income tax for the period, completing the transition from pretax income to net income. Relative to period-end equity, the net loss represented 190.9%. The loss-to-assets relationship was 139.4%, placing the bottom-line deficit against the company’s resource base. The net loss widened to $25.32M from $19.90M in fiscal 2024.

Liquidity and Capital Structure

Total assets were $18.16M, supported by $4.90M of liabilities and $13.26M of shareholder equity. Current assets were $16.67M against $4.43M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 3.77x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. The equity-to-assets relationship was 73.0%, placing book capital against the total resource base. Liabilities represented 27.0% of total assets, quantifying the liability-funded share of the company’s resource base. Compared with $16.80M in fiscal 2024, the current asset base moved 8.1% and finished higher.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $22.86M, rather than cash generation from operations. The company spent $90.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Operating cash flow and capital spending combined to leave a $22.95M cash deficit after capital spending. Relative to revenue, the post-investment cash deficit represented 169.4%. Relative to total assets, the post-investment cash deficit measured 126.4%. The operating cash outflow widened to $22.86M from $20.09M in fiscal 2024.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for CapsoVision, Inc
Metric FY2025 📄 FY2024 📄
Income Statement
REVENUE
Revenue $13.55M $11.76M
Cost of Revenue $6.38M $5.38M
Gross Profit $7.17M $6.38M
OPERATING EXPENSES
R&D Expense $18.31M $15.12M
SG&A Expense $6.85M $4.21M
Other Operating Expenses (derived) $7.53M $6.97M
Operating Income $-25.52M $-19.92M
NON-OPERATING INCOME / EXPENSE
Other Income/Expense $-44.00K $4.00K
Pretax Income $-25.29M $-19.89M
Income Tax $24.00K $11.00K
Net Income $-25.32M $-19.90M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-1.03 $-9.85
Diluted Shares 24.56M 2.02M
EBITDA $-25.30M $-19.71M
Depreciation & Amortization $216.00K $206.00K
Balance Sheet
ASSETS
Accounts Receivable $2.50M $2.00M
Inventory $2.99M $2.63M
Other Current Assets $448.00K $260.00K
Current Assets $16.67M $14.85M
PP&E (Net) $611.00K $720.00K
Other Noncurrent Assets $41.00K $41.00K
Noncurrent Assets $1.50M $1.96M
Total Assets $18.16M $16.80M
LIABILITIES
Accounts Payable $1.14M $749.00K
Other Current Liabilities $519.00K $140.00K
Current Liabilities $4.43M $1.80M
Noncurrent Liabilities $477.00K $887.00K
Total Liabilities $4.90M $2.69M
EQUITY
Common Stock $47.00K $2.00K
Additional Paid-in Capital $168.88M $838.00K
Retained Earnings $-155.67M $-130.35M
Total Equity $13.26M $-129.51M
Temporary Equity $0 $143.63M
Total Liabilities & Equity $18.16M $16.80M
SUPPLEMENTAL
Shares Outstanding 46.87M 2.09M
Check: A − (L + E + Temp. Equity) - -
Cash Flow Statement
Cash from Operations $-22.86M $-20.09M
Capital Expenditures $90.00K $153.00K
Cash from Investing $-90.00K $-153.00K
Cash from Financing $23.60M $15.07M
Free Cash Flow $-22.95M $-20.24M
Beginning Cash (CFS) $9.32M $14.56M
Net Change in Cash $650.00K $-5.17M
Effect of FX on Cash $143.00K $-70.00K
Calculated Ending Cash $10.11M $9.32M
Cash per BS - -
Cash scope difference (CFS − BS) - -
Cash per CFS $10.11M $9.32M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is CapsoVision, Inc's annual revenue?

CapsoVision, Inc reported $13.89M in revenue for trailing twelve months (ending June 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is CapsoVision, Inc profitable?

No. CapsoVision, Inc reported $-29.83M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does CapsoVision, Inc generate free cash flow?

No. Free cash flow was $-27.89M for trailing twelve months. Operating cash flow was $-27.82M.